DE69421457D1 - Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen - Google Patents

Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen

Info

Publication number
DE69421457D1
DE69421457D1 DE69421457T DE69421457T DE69421457D1 DE 69421457 D1 DE69421457 D1 DE 69421457D1 DE 69421457 T DE69421457 T DE 69421457T DE 69421457 T DE69421457 T DE 69421457T DE 69421457 D1 DE69421457 D1 DE 69421457D1
Authority
DE
Germany
Prior art keywords
treatment
obsessive
compulsive
pyridinyl
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69421457T
Other languages
English (en)
Other versions
DE69421457T2 (de
Inventor
Sathapana Kongsamut
Craig Paul Smith
Ann Theresa Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of DE69421457D1 publication Critical patent/DE69421457D1/de
Application granted granted Critical
Publication of DE69421457T2 publication Critical patent/DE69421457T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69421457T 1993-07-19 1994-07-13 Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen Expired - Lifetime DE69421457T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/092,848 US5356910A (en) 1993-07-19 1993-07-19 Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder

Publications (2)

Publication Number Publication Date
DE69421457D1 true DE69421457D1 (de) 1999-12-09
DE69421457T2 DE69421457T2 (de) 2000-05-04

Family

ID=22235450

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69421457T Expired - Lifetime DE69421457T2 (de) 1993-07-19 1994-07-13 Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen

Country Status (21)

Country Link
US (1) US5356910A (de)
EP (1) EP0635269B1 (de)
JP (1) JP2807633B2 (de)
KR (1) KR100325276B1 (de)
AT (1) ATE186215T1 (de)
AU (1) AU673747B2 (de)
CA (1) CA2128312C (de)
CZ (1) CZ288593B6 (de)
DE (1) DE69421457T2 (de)
DK (1) DK0635269T3 (de)
EG (1) EG20716A (de)
ES (1) ES2138017T3 (de)
GR (1) GR3032292T3 (de)
HU (1) HU217063B (de)
MX (1) MX9405209A (de)
NO (1) NO306597B1 (de)
NZ (1) NZ264015A (de)
PL (1) PL304335A1 (de)
RU (1) RU2164795C2 (de)
TW (1) TW349864B (de)
ZA (1) ZA945236B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
CA2225156C (en) * 1995-07-27 2003-06-10 Hoechst Marion Roussel, Inc. Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents
HUP9802413A3 (en) * 1995-07-27 2002-02-28 Aventis Pharmaceuticals Inc Br Use of n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents and for the preparation of a pharmaceutical composition for the treatment of convulsions
JP4608723B2 (ja) * 1999-03-10 2011-01-12 東ソー株式会社 置換インドール誘導体の製造方法
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
FR2897614B1 (fr) * 2006-02-20 2008-05-23 Urogene Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (de) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
US5179099A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-dihydro-1-(pyridinylamino)-indoles
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5177088A (en) 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
US5185350A (en) 1991-09-23 1993-02-09 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1h-indoles,1h-indazoles,2h-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
DK0635269T3 (da) 2000-04-25
CZ288593B6 (cs) 2001-07-11
CZ173094A3 (en) 1995-02-15
NO942695L (no) 1995-01-20
PL304335A1 (en) 1995-01-23
AU673747B2 (en) 1996-11-21
CA2128312A1 (en) 1995-01-20
ATE186215T1 (de) 1999-11-15
JPH0753376A (ja) 1995-02-28
GR3032292T3 (en) 2000-04-27
ZA945236B (en) 1995-02-28
HU217063B (hu) 1999-11-29
NZ264015A (en) 1997-07-27
EP0635269A1 (de) 1995-01-25
NO942695D0 (no) 1994-07-18
JP2807633B2 (ja) 1998-10-08
EG20716A (en) 1999-12-29
HU9402124D0 (en) 1994-09-28
ES2138017T3 (es) 2000-01-01
DE69421457T2 (de) 2000-05-04
RU2164795C2 (ru) 2001-04-10
AU6753194A (en) 1995-01-27
US5356910A (en) 1994-10-18
KR950002761A (ko) 1995-02-16
TW349864B (en) 1999-01-11
KR100325276B1 (ko) 2002-09-25
CA2128312C (en) 2004-09-28
NO306597B1 (no) 1999-11-29
HUT69709A (en) 1995-09-28
MX9405209A (es) 1995-01-31
RU94026084A (ru) 1996-08-27
EP0635269B1 (de) 1999-11-03

Similar Documents

Publication Publication Date Title
HU9600834D0 (en) Quinazoline derivatives
DE69810134T2 (de) Amide derivativen zur behandlung von durch cytokinen vermittelten krankheiten
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE168007T1 (de) Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole
CA2241904A1 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
DE69421457D1 (de) Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
DE69906728D1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen
DE69619088T2 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69327077T2 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMACEUTICALS INC., BRIDGEWATER, N.J, US

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US

8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT